ATMPs (advanced therapy medicinal products) open a decisive front: costs are concentrated in the present, while benefits accrue over the years. Rethinking capital, accounting, and payment models is now essential to ensure access and sustainability. Prof. Mauro Marè (LUISS) explains this in an interview: https://formiche.net/2025/11/atmp-terapie-avanzate-investimenti-intervista-mare/#content
At the same time, the new bill on advanced therapies is being presented in the Senate, with the ambition of proposing a model that combines equitable access, sustainability, and national industrial capacity, while also asking Europe to recognize these expenses as strategic investments. Conversation with Senator Francesco Zaffini published by Formiche: https://formiche.net/2025/11/italia-europa-innovazione-terapie-avanzate-atmp-zaffini/#content
